Optimizing Frontline Therapy for CML: Balancing Efficacy, Safety, and Long-Term Tolerability

Meeting Objectives:

• • Evaluate recent evidence and advances in frontline treatment of currently available TKIs for chronic-phase (CP) CML.
  • Discuss current guidelines and real world clinical evidence that influence long-term TKI use such as adherence, toxicity management, and the feasibility of sustaining therapy over time.
  • Explore the pharmacist’s role in optimizing adherence, managing adverse effects, and addressing access barriers in CP-CML care.